Parkinson's Disease Market Anticipated To Witness Robust Growth, Surpassing 4.97 Billion By 2029

"We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.

What Is the Current Parkinson's Disease Market Size and Its Estimated Growth Rate?
In the recent past, the market size of Parkinson's disease has seen robust growth. Its worth is predicted to rise from $3.34 billion in 2024 to $3.63 billion in 2025, marking a compound annual growth rate (CAGR) of 8.5%. The expansion during the historical period can be linked to factors such as enhanced research and development, increased government funding, a surge in personalized care strategies, a rise in support structures for those suffering from Parkinson's disease, and the escalated use of sophisticated rehabilitation therapies.

Forecasted robust expansion is expected in the Parkinson's disease market in the coming years, with its value anticipated to reach $4.98 billion in 2029, growing at a compound annual growth rate (CAGR) of 8.2%. Factors accelerating this growth during the forecast period include heightened awareness regarding symptoms of Parkinson's disease, increased governmental efforts, escalated healthcare investments, a growing count of clinical trials for Parkinson's disease, and a higher acceptance rate of gene therapies. Noteworthy trends predicted during the projection period comprise technological breakthroughs, government incentives and financial backing, employment of artificial intelligence in diagnosis procedures, innovative solutions development, and rise in personalized medicine.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21247

How Are Emerging Segments Shaping the Parkinson's Disease Market Landscape?
The parkinson's disease market covered in this report is segmented -

1) By Drug Class: Dopamine Agonists, Catechol-O-Methyltransferase Inhibitors, Monoamine Oxidase B Inhibitors, Anticholinergics, Carbidopa-Levodopa, Other Drug Classes
2) By Route Of Administration: Oral, Injectable, Intestinal infusion, Subcutaneous, Other Route Of Administrations
3) By Distribution Channel: Retail Pharmacies, Hospital Pharmacies, Online Pharmacies
4) By Patient Care Setting: Clinics, Hospitals

Subsegments:
1) By Dopamine Agonists: Ergot Derivatives, Non-Ergot Derivatives
2) By Catechol-O-Methyltransferase (COMT) Inhibitors: Entacapone, Tolcapone, Opicapone
3) By Monoamine Oxidase B (MAO-B) Inhibitors: Selegiline, Rasagiline, Safinamide
4) By Anticholinergics: Trihexyphenidyl, Benztropine, Procyclidine
5) By Carbidopa-Levodopa: Immediate-Release Formulation, Extended-Release Formulation, Inhaled And Intestinal Gel Formulations
6) By Other Drug Classes: Amantadine And Derivatives, Adenosine A2A Receptor Antagonists, Glutamate Antagonists

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21247&type=smp

Which Growth Factors Are Influencing Parkinson's Disease Market Expansion?
The escalating occurrence of neurodegenerative disorders is anticipated to drive the expansion of the parkinson's disease market. Neurodegenerative disorders encompass a set of diseases characterized by the gradual decay and functional loss of brain and nervous system neurons. The escalating instances of such diseases can be credited to factors such as elderly populations, hereditary inclinations, environmental factors, enhanced diagnostic methods, escalating chronic health issues, and lifestyle shifts. Parkinson's disease contributes significantly to comprehending neurodegenerative diseases by providing essential insights into their deep-seated mechanisms, potential therapeutic targets, and the generation of novel treatment methodologies. For instance, in April 2022, the European Brain Council, a non-profit organization based in Belgium, revealed that over 600 neurological diseases and about 300 psychiatric conditions affect millions worldwide, including 65 million epilepsy sufferers. In Europe alone, around 10.5 million individuals suffer from dementia, with projections suggesting an increase to 18.7 million by 2050. Consequently, the escalating occurrence of neurodegenerative diseases is fueling the expansion of the parkinson's disease market.

Who Are the Dominant Players Across Different Parkinson's Disease Market Segments?
Major companies operating in the parkinson's disease market are Roche Holding AG, AbbVie Inc., Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, UCB S.A., Eisai Co. Ltd., Kyowa Kirin Co. Ltd., Amneal Pharmaceuticals Inc., Neurocrine Biosciences Inc., Supernus Pharmaceuticals Inc., Sunovion Pharmaceuticals Inc., Intracellular Therapies Inc., Voyager Therapeutics Inc., Sage Therapeutics Inc., Adamas Pharmaceuticals Inc., Sun Pharma Advanced Research Company Ltd., Neuraly Inc., Mitsubishi Tanabe Pharma Corporation, Athira Pharma Inc., VistaGen Therapeutics Inc.

What Trends Are Expected to Dominate the Parkinson's Disease Market in the Next 5 Years?
Major firms in the Parkinson's disease market are prioritizing the development of novel solutions like levodopa-based therapies. These are designed to enhance motor function and provide ongoing symptom control for individuals with advanced Parkinson's disease. Levodopa-based therapy utilizes the drug levodopa, which turns into dopamine in the brain, to boost motor function and relieve Parkinson's disease symptoms. AbbVie Inc., a leading US biopharmaceutical company, for example, received FDA approval for VYALEV, a combination therapy involving levodopa and carbidopa, specifically formulated for treating Parkinson's disease, in October 2024. The goal of this formulation is to enhance the efficiency of levodopa by preventing it from breaking down before it reaches the brain, resulting in amplified dopamine levels. This medication effectively manages motor symptoms such as tremors, rigidity, and bradykinesia associated with Parkinson's disease, subsequently improving the patient's ability to undertake routine tasks. It is thus acknowledged as a primary therapeutic option for Parkinson's disease patients who experience motor fluctuations.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/parkinsons-disease-global-market-report

Which Geographic Regions Are Expected to Dominate the Parkinson's Disease Market in the Coming Years?
North America was the largest region in the parkinson's disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the parkinson's disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Parkinson's Disease Market?
2. What is the CAGR expected in the Parkinson's Disease Market?
3. What Are the Key Innovations Transforming the Parkinson's Disease Industry?
4. Which Region Is Leading the Parkinson's Disease Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments."

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ"

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.